MediWound Ltd (M8W) - Total Liabilities
Based on the latest financial reports, MediWound Ltd (M8W) has total liabilities worth €44.27 Million EUR (≈ $51.75 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MediWound Ltd cash flow conversion to assess how effectively this company generates cash.
MediWound Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how MediWound Ltd's total liabilities have evolved over time, based on quarterly financial data. Check MediWound Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.
MediWound Ltd Competitors by Total Liabilities
The table below lists competitors of MediWound Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Banco Hipotecario SA
BA:BHIP
|
Argentina | AR$3.59 Trillion |
|
Bukaka Teknik Utama Tbk Pt
JK:BUKK
|
Indonesia | Rp15.93 Trillion |
|
E-World
KO:084680
|
Korea | ₩191.95 Billion |
|
JCY International Bhd
KLSE:5161
|
Malaysia | RM113.43 Million |
|
Cabral Gold Inc
V:CBR
|
Canada | CA$1.68 Million |
|
Turk Prysmian Kablo ve Sistemleri AS
IS:PRKAB
|
Turkey | TL5.96 Billion |
|
Paninvest Tbk
JK:PNIN
|
Indonesia | Rp174.16 Trillion |
Liability Composition Analysis (2016–2024)
This chart breaks down MediWound Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of MediWound Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MediWound Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MediWound Ltd (2016–2024)
The table below shows the annual total liabilities of MediWound Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €42.34 Million ≈ $49.50 Million |
+21.45% |
| 2023-12-31 | €34.86 Million ≈ $40.76 Million |
-10.84% |
| 2022-12-31 | €39.10 Million ≈ $45.71 Million |
+60.74% |
| 2021-12-31 | €24.33 Million ≈ $28.44 Million |
+2.22% |
| 2020-12-31 | €23.80 Million ≈ $27.82 Million |
-6.38% |
| 2019-12-31 | €25.42 Million ≈ $29.72 Million |
-3.36% |
| 2018-12-31 | €26.30 Million ≈ $30.75 Million |
-23.79% |
| 2017-12-31 | €34.52 Million ≈ $40.35 Million |
+23.29% |
| 2016-12-31 | €27.99 Million ≈ $32.73 Million |
-- |
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more